Search for a trial

A clinical performance study for testing FFPE tissue samples, with therascreen® KRAS RGQ PCR kit, to determine KRAS G12C mutation for potential enrollment into clinical study BO45217

The objective of the diagnostic performance study is to determine the KRAS G12C status in tissues of NSCLC tumors collected from potential study subjects, in order to determine their biomarker eligibility for study BO45217. Currently, there is no…

An interventional, prospective IVD device study for the testing of DNA extracted from tumor tissue biopsy samples from adult participants with metastatic Non-Small Cell Lung Cancer (NSCLC) for potential inclusion in the MSD Phase 3 clinical trial (Protocol No MK-1084-004) to demonstrate clinical performance of the therascreen® KRAS RGQ PCR Kit.

To utilize the therascreen KRAS RGQ PCR Kit (KRAS Kit) as a screening test to identify KRAS G12C mutations in newly diagnosed metastatic NSCLC participants and thereby determine eligibility for enrolment into the Phase 3 clinical study (MK-1084-004…

A performance evaluation study for the testing of DNA extracted from tumor tissue samples, using the therascreen® KRAS RGQ PCR Kit, from participants with Non-Small Cell Lung Cancer in Lilly*s Clinical Trial (Protocol No. J3M-MC-JZQB/ SUNRAY-01) in order to generate data to demonstrate the performance of the kit as a CDx.

For Lilly's study (drug study)Primary Objectives:Dose Optimization- To determine the optimal dose of LY3537982 (50 or 100 mg BID) to be administered in combination with pembrolizumabSafety Lead-In- To determine the dose of LY3537982 to be…